Positioning no disclosures inside 60 days, left as found
Options put/call open interest 6.33, read 2026-11-01
Ethical does not pass the values gate
Price72.73 USD
Fair value77.32
Ethical score10.0/100
Value readFairas of 5 Nov 2026
Our investment reviews on this name
2026-11-05Read Distribution77.88-6.6% to today ✓Markdown gives way to Distribution after a 13% slide in 4 weeks
2026-10-10Read Markdown89.24-18.5% to today ✓Distribution gives way to Markdown with results news in the headlines
2026-10-02Read Distribution89.24-18.5% to today ✓Markup gives way to Distribution
2026-08-01Read Markup91.74-20.7% to today Accumulation gives way to Markup after a 9% rise in 4 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Interactive Brokers holds its Distribution at $72.73. The statistical read favours the sellers, held for 1 days.
As held on the ledger · 2026-11-05
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 1 days
Price at the screen
$72.73
Valuation
31.21 trailing · 24.61 forward price to earnings
Values screen
FAIL· score 10.0
Beta
1.37
The Workings
Five Screens, Shown in Full
Does not pass. Business activity screen
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Business activity: Financials sector
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Interactive Brokers does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when IBKR's ethical verdict changes
Today IBKR does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 5 Nov 2026: it trades above our $77.32 fair value estimate, moderate competitive moat, 13.50% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 5.9% discount to the base estimate.
Third-party analyst targets: 16 covering, consensus Buy. The average target sits +44% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $77.32, with a range of $67.50 to $88.92, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it is worth knowing
A quality business: a moderate moat and 17% profit margins. At the screened price it sits 1% above our $77.32 fair value: priced for the quality, not a bargain.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
IBKR trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 3.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (10 analysts) rates it buy, with a mean price target of $86.
2026-10-29Markdown$80.28-6.7%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (10 analysts) rates it buy, with a mean price target of $86.
2026-10-22Markdown$86.03-2.1%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (10 analysts) rates it buy, with a mean price target of $86.
2026-10-15Markdown$87.87+0.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (10 analysts) rates it buy, with a mean price target of $86. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-14Markdown$87.87+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (10 analysts) rates it buy, with a mean price target of $86. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-13Markdown$87.87+0.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (10 analysts) rates it buy, with a mean price target of $86. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-12Markdown$87.87-1.5%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (10 analysts) rates it buy, with a mean price target of $86. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-11Markdown$89.24+0.0%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (10 analysts) rates it buy, with a mean price target of $86. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-10Markdown · changed$89.24+0.0%Entry 7
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (10 analysts) rates it buy, with a mean price target of $86. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (10 analysts) rates it buy, with a mean price target of $86.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
